8-K: Mural Oncology Shareholders Approve XOMA Royalty Acquisition

Mural Oncology plc shareholders overwhelmingly approved the proposed acquisition by XRA 5 Corp., a subsidiary of XOMA Royalty Corporation, paving the way for completion in Q4 2025.

Summary

• Shareholders of Mural Oncology plc approved the proposed acquisition by XRA 5 Corp., a wholly-owned subsidiary of XOMA Royalty Corporation, via a scheme of arrangement under Irish law.
• At the Scheme Meeting on October 24, 2025, Proposal 1, to agree to the Scheme, was approved with 10,103,706 votes For, 81,149 Against, and 52,031 Abstain.
• The Scheme Meeting approval represented a majority in number of shareholders present and voting, and at least 75% of the value of shares voted.
• At the Extraordinary General Meeting (EGM) on October 24, 2025, Proposal 1, to approve the Scheme of Arrangement and authorize directors, was approved with 10,607,228 votes For, 89,435 Against, and 13,056 Abstain.
• EGM Proposal 2, to amend the company's articles of association to ensure newly issued shares are subject to the Scheme or acquired by Sub, was approved with 10,647,967 votes For, 48,436 Against, and 13,316 Abstain.
• Proposals to adjourn either meeting were not presented as sufficient votes were secured for all substantive proposals.
• The acquisition is expected to be completed during the fourth quarter of 2025, subject to customary closing conditions and sanction by the High Court of Ireland.

Sentiment

Score: 8

Explanation: The filing reports the successful and overwhelming shareholder approval of a planned acquisition, which is a significant positive step towards the transaction's completion. This indicates strong progress on a major strategic event.

Positives

• Shareholders overwhelmingly approved all proposals necessary for the acquisition to proceed, indicating strong support for the transaction.
• The successful vote provides a clear path towards the completion of the acquisition by XOMA Royalty Corporation.
• The expected completion in Q4 2025 provides a defined timeline for the transaction.

Risks

• The acquisition is subject to the satisfaction of customary closing conditions.
• The Scheme of Arrangement requires sanction by the High Court of Ireland, which may not be received.
• General risks and uncertainties pertaining to Mural Oncology's business, as described in its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and subsequent SEC filings.
• Potential risks and uncertainties related to XOMA Royalty, as described in its most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other SEC filings.

Future Outlook

The acquisition is expected to be completed during the fourth quarter of 2025, contingent upon the satisfaction of customary closing conditions and the sanction of the Scheme of Arrangement by the High Court of Ireland.

Management Comments

• The Directors of the Company accept responsibility for the information contained in this communication, confirming it is in accordance with the facts and does not omit anything likely to affect its import.

Industry Context

This announcement reflects a common trend in the biotechnology and pharmaceutical sectors where smaller companies are acquired by larger entities or royalty companies, often to integrate pipelines or leverage existing assets. The use of a scheme of arrangement under Irish law is a standard legal mechanism for such transactions involving Irish-domiciled companies.

Corporate Governance

Stakeholder Impact

• Shareholders: The overwhelming approval indicates shareholder support for the acquisition, which will result in them receiving consideration for their shares upon completion.
• Employees: The acquisition will likely lead to integration and potential changes in management structure or operations, impacting employees.
• Customers/Suppliers: Changes in ownership can affect existing relationships and future business dealings.

Next Steps

• Satisfaction of customary closing conditions for the acquisition.
• Sanction of the Scheme of Arrangement by the High Court of Ireland.
• Completion of the acquisition during the fourth quarter of 2025.

Key Dates

Recommendation

The shareholder approval confirms the acquisition is on track for completion in Q4 2025. For existing shareholders, holding shares until the acquisition closes is advisable to receive the agreed-upon scheme consideration. For new investors, the upside is limited by the fixed acquisition price, making it less attractive for a 'buy' unless engaging in a specific arbitrage strategy.

Keywords

Mural Oncology, XOMA Royalty, Acquisition, Scheme of Arrangement, Shareholder Vote, M&A, Biotechnology, Ireland, SEC Filing, 8-K